文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

常见髂淋巴结阳性前列腺癌根治性放疗:N1还是M1a

Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-21

本研究比较了常见髂(CI)淋巴结阳性(CI-M1a)与盆腔淋巴结阳性(cN1)前列腺癌患者接受根治性全盆腔放疗和长期雄激素剥夺治疗(ADT)后的结局。中位随访61个月,两组生化失败率、5年生化无失败生存、无远处转移生存和总生存均相似。作者认为这些寡转移患者的治疗应前瞻性评估。

要点

  • CI-M1a与cN1患者接受根治性全盆腔放疗和长期ADT后,生化失败率相似(25.6% vs 24.1%,P=0.86)。
  • 两组5年生化无失败生存(70.4% vs 77.4%,P=0.43)、无远处转移生存(79.4% vs 86.9%,P=0.23)和总生存(90.1% vs 92.6%,P=0.80)均相似。
  • CI-M1a组内近端与远端髂淋巴结位置者的结局相似,5年生化无失败生存分别为73.6%与58.6%(P=0.81)。

核心结论

  • 寡转移性CI-M1a与cN1前列腺癌患者接受根治性全盆腔放疗和长期ADT后结局相似。
  • 作者认为这些寡转移患者的治疗应前瞻性评估。

研究设计与样本

  • 从前瞻性维护的数据库中识别CI-M1a或cN1淋巴结阳性前列腺腺癌患者。
  • 超过75%的患者在诊断时接受镓68前列腺特异性膜抗原(Ga68-PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)分期。
  • 所有患者接受长期ADT以及针对前列腺和盆腔(包括CI区域)的中度或极度大分割放疗。
  • 生化失败(BCF)时使用Ga68-PSMA-PET/CT再分期以确定失败模式。
  • CI-M1a队列按近端或远端CI淋巴结位置分类并研究结局。

主要发现

  • 共分析130例患者,其中87例为cN1,43例为CI-M1a。
  • 放疗前ADT中位持续时间为7个月,总持续时间至少24个月。
  • 大多数患者(65%)为Gleason分级组IV至V,75%为≥T3期疾病。
  • 中位随访61个月后,两组BCF相似(cN1:87例中21例,24.1%;CI-M1a:43例中11例,25.6%;P=0.86)。
  • BCF时再分期Ga68-PSMA-PET/CT在32例中20例(63%;cN1为57%,CI-M1a为73%;P=0.47)发现远处转移。

关键数值与推荐

  • 5年生化无失败生存:cN1为77.4%,CI-M1a为70.4%(P=0.43)。
  • 5年无远处转移生存:cN1为86.9%,CI-M1a为79.4%(P=0.23)。
  • 5年总生存:cN1为92.6%,CI-M1a为90.1%(P=0.80)。
  • CI-M1a组内近端与远端CI淋巴结位置的5年生化无失败生存分别为73.6%与58.6%(P=0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为这些寡转移患者的治疗应前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Common iliac (CI) nodes are staged as (oligo)metastatic M1a for prostate cancer. Whether outcomes of pelvic node-positive (cN1) differ from CI node-positive (CI-M1a) prostate cancer after curative treatment is unclear. The present study compares outcomes in patients treated with radical whole pelvic radiation therapy (RT) and long-term androgen deprivation therapy (ADT). METHODS AND MATERIALS: Patients with a node-positive adenocarcinoma prostate were identified, either CI-M1a or cN1, from a prospectively maintained database. More than 75% of patients were staged with Gallium (Ga) 68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) at the time of diagnosis. All patients received long-term ADT and moderately or extremely hypofractionated RT to the prostate and pelvis, including the CI region. At the time of biochemical failure (BCF), restaging was done with Ga68-PSMA-PET/CT to establish the patterns of failure. The CI-M1a cohort was classified as proximal or distal CI nodal location, and studied for outcomes. RESULTS: Of the 130 patients analyzed, 87 had cN1 and 43 had CI-M1a stage disease. The median duration of ADT before RT was 7 months, and total duration was at least 24 months. The majority of patients (65%) had Gleason grade group IV to V, and 75% had ≥T3 disease. After a median follow up of 61 months, BCF in the 2 groups was similar (cN1: n = 21 of 87; 24.1%; CI-M1a: n = 11 of 43; 25.6%; P = .86). At the time of BCF, restaging Ga68-PSMA-PET/CT located distant metastases in 20 of 32 patients (63%; 57% in cN1 and 73% in CI-M1a; P = .47). In addition, the 5-year biochemical failure-free (cN1: 77.4%; CI-M1a: 70.4%; P = .43), distant metastasis-free (cN1: 86.9%; CI-M1a: 79.4%; P = .23), and overall (cN1: 92.6%; CI-M1a 90.1%; P = .80) survival were similar in the 2 groups. Outcomes within CI-M1a were similar for proximal versus distal CI nodal location and 5-year biochemical failure-free survival (73.6% vs 58.6%; P = .81). CONCLUSIONS: Patients with oligometastatic CI-M1a and cN1 prostate cancer showed similar outcomes when treated with curative whole pelvic RT and long-term ADT. The treatment for these oligometastatic patients should be prospectively evaluated.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chopade P, Maitre P, David S, et al. Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a? Int J Radiat Oncol Biol Phys. 2022. PMID: 35870708. doi:10.1016/j.ijrobp.2022.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。